Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-positive Pap smear samples compared to normal cytology HPV-positive Pap smear samples.

BACKGROUND: The human papillomavirus (HPV) infection may affect the miRNA expression pattern during cervical cancer (CC) development. To demonstrate the association between high-risk HPVs and the development of cervix dysplasia, we examined the expression patterns of hsa-miR-194-5p and hsa-miR-195-5p in Pap smear samples from southeast Iranian women. We compared samples that were HPV-positive but showed no abnormality in the cytological examination to samples that were HPV-positive and had severe dysplasia. METHODS: Pap smear samples were obtained from 60 HPV-positive (HPV-16/18) patients with histologically confirmed severe dysplasia (cervical intra-epithelial neoplasia (CIN 3) or carcinoma in situ) and the normal cytology group. The expression of hsa-miR-194-5p and hsa-miR-195-5p was analyzed by real-time quantitative PCR, using specific stem-loop primers and U6 snRNA as the internal reference gene. Clinicopathological features were associated with miRNA expression levels. Furthermore, functional enrichment analysis was conducted using in silico tools. The Kaplan-Meier survival method was also obtained to discriminate survival-significant candidate miRNAs in CC, and receiver operating characteristic (ROC) curves were constructed to assess the diagnostic value. RESULTS: Compared to HPV-positive cytologically normal Pap smear samples, hsa-miR-194-5p and hsa-miR-195-5p relative expression decreased significantly in HPV-positive patients with a severe dysplasia Pap smear. Kaplan-Meier analysis indicated a significant association between the miR-194 decrease and poor CC survival. In essence, ROC curve analysis showed that miR-194-5p and miR-195-5p could serve as valuable markers for the development of cervix dysplasia in individuals who are positive for high-risk HPVs. CONCLUSIONS: This study revealed that hsa-miR-194-5p and hsa-miR-195-5p may possess tumor suppressor capabilities in the context of cervical dysplasia progression. However, it remains uncertain whether these microRNAs are implicated in the transition of patients with high dysplasia to cervical cancer. We also showed the potential capability of candidate miRNAs as novel diagnostic biomarkers related to cervical dysplasia progression.

Royal Jelly Nanoparticle Alleviates Experimental Model of Breast Cancer Through Suppressing Regulatory T Cells and Upregulating TH1 Cells.

BACKGROUND: Royal jelly, a natural product from bees' hypopharyngeal glands, is commonly used in biomedicine due to its antioxidant and anti-tumor activities. The aim of this study was to compare royal jelly in free form and loaded in layered double hydroxide (LDH) nanoparticle for the treatment of breast cancer with a focus on Th1 and T regulatory parameters in an animal model. METHODS: Nanoparticles were produced using the coprecipitation method and characterized using DLS, FTIR, and SEM techniques. Forty female BALB/c mice were inoculated with 7.5 x 105 4T1 cells and treated with royal jelly in free and nanoparticle form. Clinical signs and tumor volume were assessed weekly. The effect of royal jelly products on the serum level of IFN-γ and TGF-ß was measured by ELISA. In addition, the mRNA expression of these cytokines and Th1 and regulatory T cells' transcription factors (T-bet and FoxP3) was assessed by real-time PCR in the splenocytes of tumor-bearing mice. RESULTS: The physicochemical analysis of nanoparticles confirmed the synthesis of LDH nanoparticles and loading of royal jelly into the LDH structures (RJ-LDH). Animal studies showed that royal jelly and RJ-LDH significantly reduced the size of tumor in BALB/c mice. Additionally, treatment with RJ-LDH significantly inhibited TGF-ß and increased IFN-γ production. The data also revealed that RJ-LDH inhibited the differentiation of regulatory T cells, while promoting Th1 cell differentiation via regulating their master transcription factors. CONCLUSIONS: These results indicated that royal jelly and RJ-LDH could inhibit breast cancer progression by in-hibiting regulatory T cells and expansion of Th1 cell. Furthermore, the current study demonstrated the therapeutic efficacy of royal jelly is enhanced by LDH nanoparticles; hence, RJ-LDH is significantly more efficient than Free-RJ in the treatment of breast cancer.

CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender.

INTRODUCTION: Hyper-inflammatory reactions play a crucial role in the pathogenesis of the severe forms of COVID-19. However, clarification of the molecular basis of the inflammatory-related factors needs more consideration. The aim was to evaluate the gene expression of two fundamental molecules contributing to the induction of inflammatory like CCR2 and DPP9 in cells from peripheral blood samples from patients with various patterns of COVID-19. METHODS: Peripheral blood samples were collected from 470 patients (235 male and 235 female) with RT-qPCR-confirmed COVID-19 test exhibiting moderate, severe, and critical symptoms based on WHO criteria. 100 healthy subjects (50 male and 50 female) were also enrolled in the study as a control group. The gene expression of DPP-9 and CCR-2 was assessed in the blood samples using real-time PCR method. RESULTS: The COVID-19 patients in severe stage expressed higher levels of CCR2 and DPP9 compared with healthy controls. In male and female patients, the levels of CCR2 and DDP9 expression significantly differed between moderate, severe, and critical patterns (p < 0.0001) as well as between each COVID-19 form and control group (p < 0.0001). The male patients with severe COVID-19 expressed greater levels of CCR2 and DPP-9 than female with same disease form. The female patients with moderate and critical COVID-19 expressed greater levels of CCR2 and DPP-9 than male patients with same disease stage. CONCLUSION: We demonstrated that the expression of DPP-9 and CCR-2 was substantially increased in COVID-19 patients with different forms of disease. Considerable differences were also demonstrated between male and female with different patterns of disease. Therefore, we suggest to consider the gender of patients and disease severity for management of COVID-19.